Explore cutting-edge strategies for managing kidney cancer as Drs. Dan George, Vasily Assikis, Naomi Haas, David Braun , Brant Inman, and Bradley McGregor present "In the Right Space at the Right Time" at 1:50 PM. #WorldGU24 #RenalCellCarcinoma #CME #CE

Another stellar talk by David Braun in #Worldgu24 World GU Conference 👉How to diagnose RCC #kidneycancer pts with residual disease after surgery? 👉liquid epigenomic profiling, CTCs (shoutout to the great Josh Lang ), Kim-1 and more👇 KidneyCAN UroToday.com OncoAlert

Thank you, my friends Neeraj Agarwal, MD, FASCO David Braun! Incredible new opportunities for our patients in a new era of liquid biopsy biomarkers! Toni Choueiri, MD Rana McKay, MD, FASCO Scott Haake, MD, PhD

Want to learn more about #renalcancer? In an episode with the Uromigos, David Braun takes a deep dive into novel #immunotherapies for the disease. Catch the podcast here➡️podcasters.spotify.com/pod/show/the-u… Yale School of Medicine | Yale Medicine

Renal cell carcinoma experts examines risk stratification strategies to guide their treatment approaches for a 59-year-old woman with #RCC. MD Anderson Cancer Center Alan Tan David Braun Katy Beckermann targetedonc.com/view/risk-stra…

Experts analyze the COSMIC-313 trial results and explore alternative treatment strategies for patients with poor-risk metastatic #RCC. MD Anderson Cancer Center Alan Tan David Braun Katy Beckermann targetedonc.com/view/cosmic-31…

I am excited to begin with my FY23 CDMRP KCRP Fellowship Award. Would appreciate my mentor David Braun for having me this amazing opportunity and wonderful projects. I thrilled to attack underlying resistant mechanisms in the aRCC. Sokuになってるけど😅↓ x.gd/jY8Lr

Here, experts evaluate strategies for monitoring treatment response in patients initiating first-line immune checkpoint inhibitor-based therapy for metastatic #RCC. #KCSM | Katy Beckermann David Braun Alan Tan targetedonc.com/view/monitorin…

Our study on sex differences in Xp11 translocation renal cell carcinoma is out Cell! We ascribe a genetic basis to the female bias in tRCC, which is driven by a translocation of the TFE3 gene on the X chromosome. w Zhang lab @danafarbernews bit.ly/4dtpNtP 🧵1/

#ICYMI... Yale #researchers, including David Braun, analyzed clinical data from 734 patients who had the same diagnosis of clear cell #kidneycancer, received the same therapy yet had different outcomes. Learn more➡️tinyurl.com/ym7dyzjr Yale Cancer Center|Smilow Cancer Hospital|Yale School of Medicine

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

David Braun Yale Cancer Center presented groundbreaking research at #KCRS24. His work with patient-derived models allows researchers to study tumor-immune interactions outside the body. Check out all the slides and videos from KCRS24 at kcrs.kidneycan.org #AcceleratingCures

Experts explore dose reduction strategies, alternative therapies, and clinical pearls for optimizing health outcomes in #RCC. #KCSM | Katy Beckermann David Braun Alan Tan targetedonc.com/view/optimizin…

My TOP 10 #GU ESMO - Eur. Oncology abstracts for #ESMO24 1/ 3

In this video, experts examine their patient population demographics and discuss the percentage of patients with clear cell #RCC who progress to receive third-line and subsequent lines of therapy. MD Anderson Cancer Center Alan Tan David Braun Katy Beckermann targetedonc.com/view/third-lin…

A very informative and important trial. Please see our commentary in The Lancet written by super star heme/onc fellow Zak Yochum Yale Hematology Oncology Fellows Yale Cancer Center Yale Pathology Yale Urology thelancet.com/journals/lance…

Congratulations to our brilliant Dr. Zachary Yochum who is first author on this commentary published in The Lancet being presented at ESMO - Eur. Oncology. Zak has been described as "a superstar" and "a pleasure to have in the lab" by our faculty and we couldn't agree more. Go Zak! 👏

An innovative approach in the biomarker quest presented by the one and only David Braun 🟢Increased glycosylation seems favorably prognostic of trt in aRCC 🟡Complement cascade and lipid metabolism proteins should be further explored for the predictive ability ‼️Still

Bravo! Chiara - beautiful presentation. Congrats to you, Roberto Iacovelli & the stellar team on intriguing data - a hugely important contribution to the emerging data on #microbiome modulation. Looking fwd to seeing next steps! #ESMO24

At #ESMO24 I got to experience again the amazing gift David Braun Yale Cancer Center has for taking complex science & distilling it in a manner relevant to a clinical audience. Super compelling data from #CM9ER evaluating #cabozantinib #nivolumab suggesting a potential predictive role